Management of low blood pressure in ambulatory heart failure with reduced ejection fraction patients

IF 16.9 1区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS European Journal of Heart Failure Pub Date : 2020-04-30 DOI:10.1002/ejhf.1835
Jennifer Cautela, Jean-Michel Tartiere, Alain Cohen-Solal, Anne Bellemain-Appaix, Alexis Theron, Thierry Tibi, James L. Januzzi Jr, Fran?ois Roubille, Nicolas Girerd
{"title":"Management of low blood pressure in ambulatory heart failure with reduced ejection fraction patients","authors":"Jennifer Cautela,&nbsp;Jean-Michel Tartiere,&nbsp;Alain Cohen-Solal,&nbsp;Anne Bellemain-Appaix,&nbsp;Alexis Theron,&nbsp;Thierry Tibi,&nbsp;James L. Januzzi Jr,&nbsp;Fran?ois Roubille,&nbsp;Nicolas Girerd","doi":"10.1002/ejhf.1835","DOIUrl":null,"url":null,"abstract":"<p>Low blood pressure is common in patients with heart failure and reduced ejection fraction (HFrEF). While spontaneous hypotension predicts risk in HFrEF, there is only limited evidence regarding the relationship between hypotension observed during heart failure (HF) drug titration and outcome. Nevertheless, hypotension (especially orthostatic hypotension) is an important factor limiting the titration of HFrEF treatments in routine practice. In patients with signs of shock and/or severe congestion, hospitalization is advised. However, in the very frequent cases of non-severe and asymptomatic hypotension observed while taking drugs with a class I indication in HFrEF, European and US guidelines recommend maintaining the same drug dosage. In instances of symptomatic or severe persistent hypotension (systolic blood pressure &lt; 90 mmHg), it is recommended to first decrease blood pressure reducing drugs not indicated in HFrEF as well as the loop diuretic dose in the absence of associated signs of congestion. Unless the management of hypotension appears urgent, a HF specialist should then be sought rather than stopping or decreasing drugs with a class I indication in HFrEF. If symptoms or severe hypotension persist, no recommendations exist. Our HF group reviewed available evidence and proposes certain steps to follow in such situations in order to improve the pharmacological management of these patients.</p>","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"22 8","pages":"1357-1365"},"PeriodicalIF":16.9000,"publicationDate":"2020-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/ejhf.1835","citationCount":"49","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Heart Failure","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/ejhf.1835","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 49

Abstract

Low blood pressure is common in patients with heart failure and reduced ejection fraction (HFrEF). While spontaneous hypotension predicts risk in HFrEF, there is only limited evidence regarding the relationship between hypotension observed during heart failure (HF) drug titration and outcome. Nevertheless, hypotension (especially orthostatic hypotension) is an important factor limiting the titration of HFrEF treatments in routine practice. In patients with signs of shock and/or severe congestion, hospitalization is advised. However, in the very frequent cases of non-severe and asymptomatic hypotension observed while taking drugs with a class I indication in HFrEF, European and US guidelines recommend maintaining the same drug dosage. In instances of symptomatic or severe persistent hypotension (systolic blood pressure < 90 mmHg), it is recommended to first decrease blood pressure reducing drugs not indicated in HFrEF as well as the loop diuretic dose in the absence of associated signs of congestion. Unless the management of hypotension appears urgent, a HF specialist should then be sought rather than stopping or decreasing drugs with a class I indication in HFrEF. If symptoms or severe hypotension persist, no recommendations exist. Our HF group reviewed available evidence and proposes certain steps to follow in such situations in order to improve the pharmacological management of these patients.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
动态心力衰竭伴射血分数降低患者低血压的处理
低血压在心力衰竭和射血分数降低(HFrEF)患者中很常见。虽然自发性低血压可以预测HFrEF的风险,但关于心力衰竭(HF)药物滴定期间观察到的低血压与预后之间的关系,只有有限的证据。然而,在常规实践中,低血压(尤其是体位性低血压)是限制HFrEF治疗滴定的一个重要因素。对于有休克和/或严重充血迹象的患者,建议住院治疗。然而,对于在服用HFrEF中I类适应症药物时观察到的非常常见的非严重和无症状低血压病例,欧洲和美国指南建议保持相同的药物剂量。对于有症状性或严重持续性低血压(收缩压90mmhg)的患者,建议首先减少HFrEF中未指征的降压药,以及在没有相关充血症状时减少循环利尿剂剂量。除非低血压治疗显得紧急,否则应该寻求心衰专科医生,而不是停止或减少对HFrEF的I类指征的药物。如果症状或严重低血压持续存在,则没有建议。我们的心衰小组回顾了现有的证据,并提出了在这种情况下应遵循的某些步骤,以改善这些患者的药理管理。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
相关文献
A Method for Calibrating Pressure by Applying the Pressure-Temperature Phase Diagram of Tin
IF 1.5 4区 物理与天体物理Japanese Journal of Applied PhysicsPub Date : 1993-01-01 DOI: 10.1143/JJAP.32.L148
Yasuo Fujinaga Yasuo Fujinaga
Influence of heating rate, temperature, pressure on the structure, and phase transition of amorphous Ni material: A molecular dynamics study.
IF 3.4 3区 材料科学ACS Applied Electronic MaterialsPub Date : 2020-11-19 DOI: 10.1016/j.heliyon.2020.e05548
Hue Dang Thi Minh, Gelu Coman, Hoc Nguyen Quang, Dung Nguyen Trong
Structure study of amorphous lead titanate by the energy-dispersive X-ray diffraction method
IF 6.1 3区 材料科学Journal of Applied CrystallographyPub Date : 1986-10-01 DOI: 10.1107/S0021889886089161
H. Ozawa, R. Uno
来源期刊
European Journal of Heart Failure
European Journal of Heart Failure 医学-心血管系统
CiteScore
27.30
自引率
11.50%
发文量
365
审稿时长
1 months
期刊介绍: European Journal of Heart Failure is an international journal dedicated to advancing knowledge in the field of heart failure management. The journal publishes reviews and editorials aimed at improving understanding, prevention, investigation, and treatment of heart failure. It covers various disciplines such as molecular and cellular biology, pathology, physiology, electrophysiology, pharmacology, clinical sciences, social sciences, and population sciences. The journal welcomes submissions of manuscripts on basic, clinical, and population sciences, as well as original contributions on nursing, care of the elderly, primary care, health economics, and other related specialist fields. It is published monthly and has a readership that includes cardiologists, emergency room physicians, intensivists, internists, general physicians, cardiac nurses, diabetologists, epidemiologists, basic scientists focusing on cardiovascular research, and those working in rehabilitation. The journal is abstracted and indexed in various databases such as Academic Search, Embase, MEDLINE/PubMed, and Science Citation Index.
期刊最新文献
Time for a new perspective on polypharmacy in heart failure Issue Information Abstracts Impact of mineralocorticoid receptor antagonists on the risk of sudden cardiac death across cardio-kidney-metabolic diseases: A meta-analysis of randomized clinical trials Ventricular arrhythmias in acute heart failure. A clinical consensus statement of the Association for Acute CardioVascular Care (ACVC), the European Heart Rhythm Association (EHRA) and the Heart Failure Association (HFA) of the ESC
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1